Suven Life Sciences Ltd
NSE:SUVEN
Suven Life Sciences Ltd
Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana and currently employs 117 full-time employees. The firm is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. The company provides a range of Drug Discovery and Development Support Services (DDDSS). The firm offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.
Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana and currently employs 117 full-time employees. The firm is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. The company provides a range of Drug Discovery and Development Support Services (DDDSS). The firm offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.
Revenue Growth: Cohance Lifesciences reported 13% year-on-year revenue growth in Q1 FY '26, with Specialty Chemicals and API as key drivers.
Pharma CDMO Performance: Pharma CDMO segment grew just 1% YoY due to inventory destocking in two large commercial molecules, but adjusted growth excluding destocking was over 30%.
Niche Technology Expansion: Revenue share from niche technologies rose to about 20% in Q1 FY '26 (from mid-teens last year), on track to reach mid-20s by year-end.
Capacity Investments: The company invested in expanding bioconjugation capacity at NJ Bio and oligonucleotide facilities at Nacharam, with both projects progressing on schedule.
Guidance Reiterated: Management reaffirmed its FY '26 and 2030 guidance, including the target to reach $1 billion (INR 85 billion) revenue by 2030 and mid-30s EBITDA margins.
Geographic Exposure: Major exports are to Europe with minimal exposure to US tariffs; agreements are typically FOB, passing tariff liability to customers.
Ongoing Destocking: Inventory destocking is expected to remain a short-term impact, mostly limited to two products in the CDMO segment.
Talent and Leadership: Cohance continues to strengthen its global leadership team and R&D talent, with no major expansion in team size planned.
